CSI Market
Sign In | Register

Theriva Biologics inc (TOVX) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access TOVX quarterly Cash Flow →
By examining cash flow figures across successive periods, users can identify shifts in Theriva Biologics inc's cash generation and deployment strategy.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-23.74
Depreciation & amortization0.11
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability9.03
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation0.65
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Stock Issued For License Fee-
Issue Of Stock For Exclusive Channel Collaboration Agreement-
Stock Issued For Consulting Fees-
Gain Loss On Derivative Instruments Net Pretax-
Change In Fair Value Of Warrant Liability-
Equipment Impairment Loss-
Gain Loss On Sale Of Accounts Receivable-
Increase Decrease In Deposits And Other Assets-
Increase Decrease In Assets Of Disposal Group Including Discontinued Operation-
Provision For Uncollectible Accounts Receivable-
Subsidary Stock Issued To Consultant-
Income Tax Expense Benefit-
Increase Decrease In Operating Lease Liability-0.19
Non Cash Lease Expense0.52
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Employee Related Liabilities-0.74
Increase (Decrease) in Accounts Payable0.07
Increase (Decrease) in Accrued Liabilities-2.28
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.46
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.56
Discontinued operations0.00
Net Cash flow from Operating Activities-16.67
Investing Activities
Capital Expenditures-0.04
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Repayment Of Long Term Loans From Vendors-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.04
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings1.51
Long-term debt - repayments-0.07
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-2.07
Stock Issued For Exclusive Channel Collaboration Agreement-
Recovery Of Direct Costs-
Proceeds From Issuance Of Common Stock For Stock Option Exercises-
Proceeds From Issuance Of Common Stock For Stock Options Exercises-
Proceeds From Issuance Of Common Stock For Exclusive Channel Collaboration Agreement-
Proceeds From Issuance Of Common Stock For Stock Option And Warrants Exercises-
Direct Offering Cost-
Proceeds From Units Offering Net Of Issuance Cost-
Proceeds From Issuance Atm Offering Net Of Issuance Costs-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents11.71
Proceeds From Issuance Under At Market Offering Net Of Issuance Costs6.83
Proceeds From Issuance Of Atm Offering Net Of Issuance Costs-
Payments For Proceeds From Tax Credit Receivable0.29
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities18.19
Effect of exchange rate on cash flow-0.09
Discontinued operations0.00
Free Cash Flow-16.70
Total Cash Flow1.40
4 historic quarters locked

Sign in to unlock the full Theriva Biologics inc cash flow history.

Sign In Create Free Account

About Theriva Biologics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001104659-26-026767

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License